Annovis Bio Inc (ANVS) - Net Assets
Based on the latest financial reports, Annovis Bio Inc (ANVS) has net assets worth $16.85 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($21.08 Million) and total liabilities ($4.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Annovis Bio Inc asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $16.85 Million |
| % of Total Assets | 79.93% |
| Annual Growth Rate | 16.44% |
| 5-Year Change | -62.13% |
| 10-Year Change | 533.3% |
| Growth Volatility | 406.17 |
Annovis Bio Inc - Net Assets Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's net assets have evolved over time, based on quarterly financial data. Check ANVS tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Annovis Bio Inc (2009–2025)
The table below shows the annual net assets of Annovis Bio Inc from 2009 to 2025. For live valuation and market cap data, see Annovis Bio Inc (ANVS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.85 Million | +81.05% |
| 2024-12-31 | $9.31 Million | +220.09% |
| 2023-12-31 | $-7.75 Million | -127.37% |
| 2022-12-31 | $28.32 Million | -36.34% |
| 2021-12-31 | $44.49 Million | +490.04% |
| 2020-12-31 | $7.54 Million | +187.93% |
| 2019-12-31 | $-8.58 Million | -12.94% |
| 2018-12-31 | $-7.59 Million | -9.02% |
| 2017-12-31 | $-6.97 Million | -361.78% |
| 2012-12-31 | $2.66 Million | -80.89% |
| 2011-12-31 | $13.93 Million | -15.56% |
| 2010-12-31 | $16.49 Million | +1017.15% |
| 2009-12-31 | $1.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Annovis Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16296421100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.72K | 0.02% |
| Other Components | $180.55 Million | 1071.45% |
| Total Equity | $16.85 Million | 100.00% |
Annovis Bio Inc Competitors by Market Cap
The table below lists competitors of Annovis Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DCM Corp
KO:024090
|
$64.80 Million |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
$64.83 Million |
|
PT Ingria Pratama Capitalindo Tbk
JK:GRIA
|
$64.83 Million |
|
Yojee Ltd
AU:YOJ
|
$64.83 Million |
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
$64.78 Million |
|
Menderes Tekstil Sanayi ve Ticaret AS
IS:MNDRS
|
$64.78 Million |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
$64.77 Million |
|
Chien Shing Stainless Steel Co Ltd
TW:2025
|
$64.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Annovis Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,307,646 to 16,851,250, a change of 7,543,604 (81.0%).
- Net loss of 28,854,197 reduced equity.
- New share issuances of 34,598,126 increased equity.
- Other factors increased equity by 1,799,675.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-28.85 Million | -171.23% |
| Share Issuances | $34.60 Million | +205.31% |
| Other Changes | $1.80 Million | +10.68% |
| Total Change | $- | 81.05% |
Book Value vs Market Value Analysis
This analysis compares Annovis Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.28x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-1.58 | $1.87 | x |
| 2018-12-31 | $-1.73 | $1.87 | x |
| 2019-12-31 | $-1.25 | $1.87 | x |
| 2020-12-31 | $1.20 | $1.87 | x |
| 2021-12-31 | $5.83 | $1.87 | x |
| 2022-12-31 | $3.47 | $1.87 | x |
| 2023-12-31 | $-0.86 | $1.87 | x |
| 2024-12-31 | $0.76 | $1.87 | x |
| 2025-12-31 | $0.82 | $1.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Annovis Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -171.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.25x
- Recent ROE (-171.23%) is below the historical average (-77.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -25.03% | -2351.46% | 0.01x | 1.03x | $-517.22K |
| 2010 | -7.98% | -18.35% | 0.33x | 1.34x | $-2.96 Million |
| 2011 | -33.93% | 0.00% | 0.00x | 1.51x | $-6.12 Million |
| 2012 | -312.86% | -4495.62% | 0.07x | 1.07x | $-8.59 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $14.21K |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $45.52K |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-133.36K |
| 2020 | -72.43% | 0.00% | 0.00x | 1.08x | $-6.22 Million |
| 2021 | -32.56% | 0.00% | 0.00x | 1.03x | $-18.94 Million |
| 2022 | -88.78% | 0.00% | 0.00x | 1.27x | $-27.98 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-55.43 Million |
| 2024 | -264.20% | 0.00% | 0.00x | 1.50x | $-25.52 Million |
| 2025 | -171.23% | 0.00% | 0.00x | 1.25x | $-30.54 Million |
Industry Comparison
This section compares Annovis Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,884,400
- Average return on equity (ROE) among peers: -49.28%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Annovis Bio Inc (ANVS) | $16.85 Million | -25.03% | 0.25x | $64.79 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $163.74 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $10.93 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.66 Billion |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more